[1] Collaborators GC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol,2020,5(3):245-266.
[2] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol,2023,79(2):516-537.
[3] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: Analysis from a chinese perspective. J Hepatol,2019,71(1):212-221.
[4] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[5] 徐京杭, 于岩岩, 徐小元. 肝硬化逆转及再代偿相关研究进展. 中华肝脏病杂志,2023,31(7):673-676.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3):S18-39.
[7] Salman MA, Mikhail HMS, Nafea MA, et al. Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-a NASH-related cirrhosis. Surg Endosc,2021,35(3):1269-1277.
[8] Wang Q, Zhao H, Deng Y, et al. Validation of baveno vii criteria for recompensation in entecavir-treated patients with hepatitis b-related decompensated cirrhosis. J Hepatol,2022,77(6):1564-1572.
[9] He Z, Zhou J, Tian Y, et al. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment hbv-related decompensated cirrhosis. Scand J Gastroenterol,2023,58(4):403-411.
[10] Li M, Zong Z, Xiong X, et al. Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy. Front Cell Infect Microbiol,2022,12:1053608.
[11] Kim TH, Um SH, Lee YS, et al. Determinants of re-compensation in patients with hepatitis b virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther,2022,55(1):83-96.
[12] 刘智慧, 王祥旭, 白引苗, 等. 恶性肿瘤肝转移假性肝硬化发生机制及诊疗的研究进展. 现代肿瘤医学,2022,30(7):1312-1315.
[13] 樊亚楠, 纪童童, 李鑫飞, 等. 双中心肝硬化住院患者临床特征与危险因素分析. 实用肝脏病杂志.2024.
[14] 徐京杭, 樊亚楠, 纪童童, 等. 500例肝硬化住院患者临床特征:一项来自北京某三甲医院的回顾性分析. 中华肝脏病杂志,2022,30(5):541-545.
[15] Tan HK, Teng MLP, Soh AYS, et al. Poor outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with hepatitis b after decompensation with ascites. Am J Gastroenterol,2021,116(7):1437-1446.
[16] Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis b patients before and after treatment. Hepatology,2017,65(5):1438-1450.
[17] Chen W, Sun Y, Chen S, et al. Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities. Hepatology,2023,78(4):1118-1132.
[18] Wang H, Wen B, Chang X, et al. Baveno vi criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed hbv-related cirrhosis. J Hepatol,2021,74(3):584-592.
[19] Wang B, Zhou J, Wu X, et al. Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with lsm. Liver Int,2021,41(2):369-377.
[20] Zhang X, Song J, Zhang Y, et al. Baveno vii algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis. J Hepatol,2023,78(3):574-583.
[21] 王哲, 胡可, 于岩岩, 等. 不同抗病毒药物对乙型肝炎肝硬化临床结局的影响. 中国实用内科杂志,2023,43(5):360-363.
[22] Chen S, Wang B, Zhou J, et al. A new glutamine synthetase index to evaluate hepatic lobular restoration in advanced fibrosis during anti-HBV therapy. J Med Virol,2023,95(2):e28555.
[23] Tosetti G, Degasperi E, Farina E, et al. Decompensation in direct-acting antiviral cured hepatitis c virus compensated patients with clinically significant portal hypertension: Too rare to warrant universal beta-blocker therapy. Am J Gastroenterol,2021,116(6):1342-1344.
[24] Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology,2020,159(4):1290-1301,e1295.
[25] Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA,2021,326(20):2031-2042.
[26] Pais R, Aron-Wisnewsky J, Bedossa P, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology,2022,76(2):456-468.
[27] Gui HL, Zhao CQ, Wang Y, et al. Histological outcome of fuzheng huayu plus entecavir combination therapy in chronic hepatitis b patients with significant liver fibrosis. J Clin Transl Hepatol,2020,8(3):277-284.
[28] Liu YQ, Zhang C, Li JW, et al. An-luo-hua-xian pill improves the regression of liver fibrosis in chronic hepatitis b patients treated with entecavir. J Clin Transl Hepatol,2023,11(2):304-313.
[29] Rong G, Chen Y, Yu Z, et al. Synergistic effect of biejia-ruangan on fibrosis regression in patients with chronic hepatitis b treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial. J Infect Dis,2022,225(6):1091-1099.
[30] Shi K, Liu Y, Wang X, et al. Adjuvant fuzheng huayu capsule reduces the incidence of hepatocellular carcinoma in patients with hepatitis b-caused cirrhosis. Evid Based Complement Alternat Med,2020,2020:8826091.
[31] Ji D, Chen Y, Bi J, et al. Entecavir plus biejia-ruangan compound reduces the risk of hepatocellular carcinoma in chinese patients with chronic hepatitis b. J Hepatol,2022,77(6):1515-1524.
[32] Cai X, Liu X, Xie W, et al. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis b: A phase 2 randomized controlled trial. Clin Gastroenterol Hepatol,2023,21(7):1893-1901,e1897.
[33] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno vii - renewing consensus in portal hypertension. J Hepatol,2022,76(4):959-974.
[34] Villanueva C, Albillos A, Genesca J, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (predesci): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet,2019,393(10181):1597-1608.
[35] Wang B, Zhou J, Wu X, et al. Carvedilol plus nucs for compensated hbv-cirrhosis patients under virological suppression: A randomised, open-label trial. Am J Gastroenterol,2023.
[36] Turco L, Reiberger T, Vitale G, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int,2023,43(6):1183-1194.
[37] 中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版). 中华肝脏病杂志,2023,31(8):813-826.
[38] Lee JI, Lee HW, Lee KS, et al. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: A nationwide nested case-control study. Am J Gastroenterol,2021,116(1):116-124.
[39] Markova AA, Deterding K, Port K, et al. Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. Eur J Gastroenterol Hepatol,2021,32(2):223-229.
[40] 靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理. 实用肝脏病杂志,2024,27(1):3-6.
[41] Baldassarre M, Naldi M, Zaccherini G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications. Hepatology,2021,74(4):2058-2073.
[42] 张舒茜, 谢雯. 有效白蛋白概念、检测及其临床应用前景. 实用肝脏病杂志.2024,27(2):165-168.
[43] Zacharias HD, Kamel F, Tan J, et al. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev,2023,7(7):CD011585. |
